Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 21;46(2):176-182.
doi: 10.1016/j.immuni.2017.02.005.

Prospects for a Zika Virus Vaccine

Dan H Barouch  1 , Stephen J Thomas  2 , Nelson L Michael  3
Affiliations
Review

Prospects for a Zika Virus Vaccine

Dan H Barouch et al. Immunity. .

Abstract

A recent unprecedented outbreak of Zika virus (ZIKV) in the Americas has been associated with microcephaly and other congenital malformations in infants as well as Guillain-Barre syndrome in adults. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Promising data from preclinical vaccine studies in mice and monkeys suggest that an effective vaccine will likely be possible, but important scientific challenges remain. Here we review the current state of ZIKV vaccine development. We discuss different vaccination strategies and we highlight challenges facing clinical evaluation of ZIKV vaccine candidates.

PubMed Disclaimer

Figures

Figure 1
Figure 1. ZIKV genomic structure and candidate vaccine immunogens
The pre-membrane (prM) and envelope (Env) proteins are shown in light and dark purple, respectively. Candidate immunogens that are currently being evaluated include full-length prM-Env, prM-Env (amino acids 216–794) with the “pr” cleavage peptide deleted (also termed “M-Env”) (Abbink et al., 2016; Larocca et al., 2016), and prM-Env with the JEV Env stem and transmembrane (TM) regions highlighted in blue (Dowd et al., 2016b).
See this image and copyright information in PMC

References

    1. Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, Kirilova M, Li Z, Ng’ang’a D, Nanayakkara O, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353:1129–1132. - PMC - PubMed
    1. Adams Waldorf KM, Stencel-Baerenwald JE, Kapur RP, Studholme C, Boldenow E, Vornhagen J, Baldessari A, Dighe MK, Thiel J, Merillat S, et al. Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate. Nat Med. 2016;22:1256–1259. - PMC - PubMed
    1. Atkinson B, Thorburn F, Petridou C, Bailey D, Hewson R, Simpson AJ, Brooks TJ, Aarons EJ. Presence and Persistence of Zika Virus RNA in Semen, United Kingdom, 2016. Emerging infectious diseases. 2017;23 - PMC - PubMed
    1. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Loriere E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536:48–53. - PubMed
    1. Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM, Ohrr HC, Tang JL, Halstead SB. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet. 2001;358:791–795. - PubMed

Publication types